News & Updates

Show Multimedia Only

Arsenic not a risk factor for prostate cancer

04 Dec 2025

Arsenic exposure in drinking water, even at high levels, does not appear to contribute to an increased risk of prostate cancer, according to a case–control study.

Arsenic not a risk factor for prostate cancer

04 Dec 2025

Ipatasertib shows promising activity against AKT1E17K-mutant tumours

04 Dec 2025

Treatment with the pan-AKT inhibitor ipatasertib appears to induce response in patients with tumours harbouring AKT1E17K mutations, according to a study.

Ipatasertib shows promising activity against AKT1E17K-mutant tumours

04 Dec 2025

$Pancreatic cancer: What’s the optimal Tx sequence for hypofractionated proton beam therapy with simultaneous integrated boost$

Pancreatic cancer: What’s the optimal Tx sequence for hypofractionated proton beam therapy with simultaneous integrated boost?

04 Dec 2025 by

Hypofractionated proton beam therapy with simultaneous integrated boost technique (SIB-PBT) can be used as a safe and effective local treatment for locally advanced pancreatic cancer (LAPC), particularly in patients with stable disease (SD) following induction chemotherapy, according to findings from the largest cohort to date presented at PTCOG-AO 2025.

Pancreatic cancer: What’s the optimal Tx sequence for hypofractionated proton beam therapy with simultaneous integrated boost?

04 Dec 2025

Original New Drug Application Approvals by US FDA (16-31 October 2025)

02 Dec 2025

New drug applications approved by US FDA as of 16-31 October 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 October 2025)

02 Dec 2025

Dietary fibre intake may lessen bowel-related symptoms in CRC survivors

30 Nov 2025

For survivors of colorectal cancer (CRC), consuming more fibre in their daily diet helps reduce bowel-related symptoms, according to a study.

Dietary fibre intake may lessen bowel-related symptoms in CRC survivors

30 Nov 2025

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

28 Nov 2025 by

A 37-year-old female non-smoker was diagnosed in 2023 with stage IV non-small-cell lung cancer (NSCLC) harbouring EGFR exon 21 L858R mutation. Lymph node (LN), lung and bone metastases were present, and her Eastern Cooperative Oncology Group (ECOG) performance status was 0. Initially, the patient’s response to standard-of-care first-line osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), was good.¹ A PET scan after 6–8 months showed that the metastases had shrunk in response to treatment. However, oligoprogression was also observed at the primary lung tumour site, which was treated with radiotherapy.

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

28 Nov 2025

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

28 Nov 2025 by

Regular monitoring and recognizing tell-tale signs upon first presentation are important in managing endocrine immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs), for optimized cancer treatment outcomes, stressed Dr David Lui from the University of Hong Kong, at the 8^th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2025).

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

28 Nov 2025

Carotenoid intake may lower CRC risk

27 Nov 2025 by

Total and selected carotenoids are inversely associated with the risk of colorectal cancer (CRC), suggests a recent study.

Carotenoid intake may lower CRC risk

27 Nov 2025

PBP superior to pericardiocentesis in reducing malignant pericardial effusion recurrence

27 Nov 2025 by

Percutaneous balloon pericardiotomy (PBP) significantly reduces recurrence of malignant pericardial effusion (MPE) by 85 percent compared with pericardiocentesis (PC), according to the randomized controlled PMAP trial conducted by a multispecialty team of researchers from the Chinese University of Hong Kong (CUHK).

PBP superior to pericardiocentesis in reducing malignant pericardial effusion recurrence

27 Nov 2025

Osimertinib linked to cardiac events in NSCLC patients

26 Nov 2025 by

Patients with non-small cell lung cancer (NSCLC) treated with osimertinib have a higher risk of QT prolongation, reduced ejection fraction, and high-grade cardiac failure than those who received placebo or other standard therapies, reports a study.

Osimertinib linked to cardiac events in NSCLC patients

26 Nov 2025

News & Updates

Filter by Specialty:

Specialty:

Arsenic not a risk factor for prostate cancer

Arsenic not a risk factor for prostate cancer

Ipatasertib shows promising activity against AKT1E17K-mutant tumours

Ipatasertib shows promising activity against AKT1E17K-mutant tumours

Pancreatic cancer: What’s the optimal Tx sequence for hypofractionated proton beam therapy with simultaneous integrated boost?

Pancreatic cancer: What’s the optimal Tx sequence for hypofractionated proton beam therapy with simultaneous integrated boost?

Original New Drug Application Approvals by US FDA (16-31 October 2025)

Original New Drug Application Approvals by US FDA (16-31 October 2025)

Dietary fibre intake may lessen bowel-related symptoms in CRC survivors

Dietary fibre intake may lessen bowel-related symptoms in CRC survivors

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

Carotenoid intake may lower CRC risk

Carotenoid intake may lower CRC risk

PBP superior to pericardiocentesis in reducing malignant pericardial effusion recurrence

PBP superior to pericardiocentesis in reducing malignant pericardial effusion recurrence

Osimertinib linked to cardiac events in NSCLC patients

Osimertinib linked to cardiac events in NSCLC patients